Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 3
1952 6
1953 1
1954 2
1955 1
1956 2
1957 2
1958 2
1959 3
1962 1
1967 1
1969 2
1970 2
1972 1
1974 1
1975 3
1976 3
1977 2
1978 4
1979 9
1980 7
1981 12
1982 16
1983 8
1984 15
1985 12
1986 8
1987 17
1988 12
1989 16
1990 9
1991 21
1992 38
1993 69
1994 57
1995 63
1996 50
1997 51
1998 113
1999 47
2000 72
2001 67
2002 67
2003 90
2004 71
2005 96
2006 118
2007 90
2008 107
2009 103
2010 141
2011 124
2012 123
2013 140
2014 146
2015 121
2016 129
2017 127
2018 141
2019 143
2020 125
2021 137
2022 99
2023 95
2024 62

Text availability

Article attribute

Article type

Publication date

Search Results

3,115 results

Results by year

Filters applied: . Clear all
Page 1
Outcome of Cyclophosphamide Treatment Following Hematopoietic Stem Cell Transplantation in a Thalassemia Patient: A Case Study.
M Bahlol H, M Khalil S, R El-Shanshory M, L Salem M. M Bahlol H, et al. Iran J Immunol. 2024 Jun 30;21(2):176-183. doi: 10.22034/iji.2024.101584.2752. Epub 2024 Jun 29. Iran J Immunol. 2024. PMID: 38943529 Free article.
Hematopoietic stem cell transplantation (HSCT) is the only curative therapy for beta-thalassemia major in children. However, it often induces graft-versus-host-disease (GVHD), which is associated with complications. ...In this case study, an 11-year-old female patie …
Hematopoietic stem cell transplantation (HSCT) is the only curative therapy for beta-thalassemia major in children. However, i …
[Overview of new approaches to beta-thalassemia treatment].
Guo XF, Han L, Zhang XC, Zhang HH, Liu J. Guo XF, et al. Sheng Li Xue Bao. 2024 Jun 25;76(3):496-506. Sheng Li Xue Bao. 2024. PMID: 38939943 Free article. Review. Chinese.
Traditional treatment modalities include blood transfusion, splenectomy, hydroxyurea therapy, and iron chelation therapy, which are now widely used for clinical treatment and constitute the main methods recommended in the beta-thalassemia treatment guidelines …
Traditional treatment modalities include blood transfusion, splenectomy, hydroxyurea therapy, and iron chelation therapy, which are now wide …
The Discovery of Selective Protein Arginine Methyltransferase 5 Inhibitors in the Management of beta-Thalassemia through Computational Methods.
Pokharel B, Ravikumar Y, Rathinavel L, Chewonarin T, Pongpom M, Tipsuwan W, Koonyosying P, Srichairatanakool S. Pokharel B, et al. Molecules. 2024 Jun 4;29(11):2662. doi: 10.3390/molecules29112662. Molecules. 2024. PMID: 38893537 Free PMC article.
beta-Thalassemia is an inherited genetic disorder associated with beta-globin chain synthesis, which ultimately becomes anemia. ...Moreover, further investigations through in vivo and in vitro experiments would unquestionably confirm that this compound could be empl
beta-Thalassemia is an inherited genetic disorder associated with beta-globin chain synthesis, which ultimately becomes anemia
Awareness and practical evaluation of correct use of iron chelators; a study to track the ambiguities of thalassemia patients on their medications in Iran.
Mousavi MS, Mohammadnezhad G, Yaghmaei F, Azarkeivan A, Esmaily H. Mousavi MS, et al. BMC Res Notes. 2024 Jun 13;17(1):163. doi: 10.1186/s13104-024-06819-3. BMC Res Notes. 2024. PMID: 38872196 Free PMC article.
PURPOSE: This study aimed to evaluate the knowledge, attitude, and practice toward iron chelating agents (ICAs) in Iranian thalassemia major patients. METHODS: A total of 101 patients with thalassemia major were involved in this cross-sectional survey. ...CONCLUSION …
PURPOSE: This study aimed to evaluate the knowledge, attitude, and practice toward iron chelating agents (ICAs) in Iranian thalassemia
Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent beta-thalassemia patients who remained on the same monotherapy over 10 years.
Musallam KM, Barella S, Origa R, Ferrero GB, Lisi R, Pasanisi A, Longo F, Gianesin B, Forni GL; Webthal® project. Musallam KM, et al. Blood Cells Mol Dis. 2024 Jul;107:102859. doi: 10.1016/j.bcmd.2024.102859. Epub 2024 May 29. Blood Cells Mol Dis. 2024. PMID: 38820707
We conducted a retrospective cohort study on 663 transfusion-dependent beta-thalassemia patients receiving the same iron chelation monotherapy with deferoxamine, deferiprone, or deferasirox for up to 10 years (median age 31.8 years, 49.9 % females). ...
We conducted a retrospective cohort study on 663 transfusion-dependent beta-thalassemia patients receiving the same iron chela …
The Effects and Safety of Silymarin on beta-thalassemia in Children and Adolescents: A Systematic Review based on Clinical Trial Studies.
Rahimi-Dehkordi N, Heidari-Soureshjani S, Mt Sherwin C. Rahimi-Dehkordi N, et al. Rev Recent Clin Trials. 2024 May 30. doi: 10.2174/0115748871305325240511122602. Online ahead of print. Rev Recent Clin Trials. 2024. PMID: 38818907
BACKGROUND: beta-thalassemia imposes significant complications on affected patients. ...CONCLUSION: Silymarin indicates promising effects on various aspects of children and adolescents with beta-thalassemia and has no serious side effects on the invest …
BACKGROUND: beta-thalassemia imposes significant complications on affected patients. ...CONCLUSION: Silymarin indicates promis …
COMPARATIVE STUDY OF OXIDATIVE STRESS IN PATIENTS WITH beta -THALASSEMIA MAJOR ON DEFERASIROX VERSUS DEFEROXAMINE THERAPY.
Neaimy K, Alsarraf O, Alkhyatt M. Neaimy K, et al. Georgian Med News. 2024 Mar;(348):99-102. Georgian Med News. 2024. PMID: 38807401
Accumulation of iron in vital organs is increasingly challenging in clinical settings during the lifespan of thalassemia patients. Iron overload hurdle these organs to redox imbalances. ...The TAOC in patients was reduced and Oxidative stress was enhanced in patient …
Accumulation of iron in vital organs is increasingly challenging in clinical settings during the lifespan of thalassemia patie …
CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments.
Laurent M, Geoffroy M, Pavani G, Guiraud S. Laurent M, et al. Cells. 2024 May 8;13(10):800. doi: 10.3390/cells13100800. Cells. 2024. PMID: 38786024 Free PMC article. Review.
In the last decade, many clinical trials were initiated and are now delivering encouraging results. The recent FDA approval of Casgevy, the first CRISPR/Cas9-based drug for severe sickle cell disease and transfusion-dependent beta-thalassemia, represents a si …
In the last decade, many clinical trials were initiated and are now delivering encouraging results. The recent FDA approval of Casgev …
The effect of aqueous extract of Iranian oak (Quercus brantii) on antioxidant capacity and oxidative stress in beta-thalassemia patients: Randomized controlled trial.
Babamir Satehi M, Karimi M, Farrokhian Z, Pakbaz F. Babamir Satehi M, et al. Clin Nutr ESPEN. 2024 Jun;61:230-236. doi: 10.1016/j.clnesp.2024.03.037. Epub 2024 Apr 4. Clin Nutr ESPEN. 2024. PMID: 38777439 Clinical Trial.
BACKGROUND AND AIM: Frequent administration of blood in beta-thalassemia patients can lead to over-loaded iron, a reduction in the levels of antioxidant activities in the body, and oxidative stress. This study was done to evaluate the antioxidant and protective effe …
BACKGROUND AND AIM: Frequent administration of blood in beta-thalassemia patients can lead to over-loaded iron, a reduction in …
3,115 results